Nmda receptor variants and calcium signaling in seizure pathogenesis

Active Grant Awarded

Award ID
RNS153215UXMNH9
Recipient
Awarding agency
Obligated
$198,751

Award facts

Completion date 0% complete
Place of performance
Stony Brook, NY 11794, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded The Research Foundation For The State University of New York, doing business as Stony Brook University, a grant of $198,751 on Nov 18, 2026, under the Neurosciences and Neurological Disorders – Research Projects (RP) program (CFDA 93.NS1).

The award funds an extramural research project titled "NMDA Receptor Variants and Calcium Signaling in Seizure Pathogenesis." The project examines missense variants in NMDA receptor subunit genes, including de novo variants in GRIN1 and GRIN2A associated with seizures, many of which current evaluation efforts leave indeterminate as loss-of-function or gain-of-function. Its central hypothesis is that differences in loss- or gain-of-function between Na+ influx and Ca2+ influx, as occur when intrinsic Ca2+ permeability is altered, represent an unrecognized factor in seizure pathogenesis.

Performance runs from the Nov 18, 2026 award date to an ultimate completion date of Nov 30, 2028, at Stony Brook, NY 11794, USA.

Description

Abstract
Nmda receptors (NMDAR) are ligand-gated ION channels activated by glutamate, contributing to excitatory neurotransmission via electrical NA+-mediated signaling and biochemical CA2+-mediated signaling. Missense variants in the genes encoding NMDAR subunits are associated with neurodevelopmental disorders, including seizures. The mechanism by which these seizure-associated variants alter brain function remains unknown. Standard treatment plans, including anti-epileptic drugs and NMDAR modulators, are largely ineffective, highlighting the need for a deeper understanding of disease mechanisms to expand treatment options. Many DE novo variants associated with seizures occur in the GRIN1 and GRIN2A genes, which encode the GLUN1 and GLUN2A subunits of nmdars, respectively. Determining whether these variants cause loss-of-function (LOF) or gain-of-function (GOF) effects is essential for understanding disease mechanisms and informing treatment strategies. However, functional classification is often challenging due to the complex and sometimes contradictory effects of individual mutations on distinct receptor properties. Current evaluation efforts, such as those by the center for functional evaluation of rare variants (CFERV), provide critical insight but many variants remain 'indeterminant' in terms of LOF or GOF because of the complex properties of nmdars. In addition, CFERV does not assess CA²⁺ permeability, a central aspect of NMDAR function. Indeed, for variants in and around the ION channel that attenuate or enhance intrinsic CA2+ permeability, LOF or GOF for CA2+ influx is not proportional to LOF or GOF for NA+-mediated membrane currents, complicating potential treatment strategies. Our central hypothesis is that variations in LOF and GOF between NA+ influx and CA2+ influx, as would occur when intrinsic CA2+ permeability is altered, represent an unrecognized factor contributing to seizure pathogenesis and complexity in grin variants. To test this hypothesis, we will assay intrinsic CA2+ permeability for variants located in and around the ION channel using HEK293 cells (aim#1.1). We will quantitively describes the impact of these variants on LOF and GOF for NA+ and CA2+ influx using an integrative approach we have developed (aim#1.2). Taking advantage of the insights and rigor generated in aim#1, we will generate a subset of variants in human embryonic stem cells to directly test how variations in NA+ and CA2+ influx alter neuronal morphology, excitability, and signaling dynamics (aim#2.1). Lastly, we will apply modulators of either nmdars or CA2+-mediated signaling pathways to these variants in an attempt restore wild-type phenotypes (aim#2.2). By quantifying core functional properties and CA2+ signaling metrics, we aim to enhance our understanding of variant-specific pathogenesis in seizure disorders to define tailored treatment strategies for patients.

Quick answers

Who received award RNS153215UXMNH9?

RNS153215UXMNH9 was awarded to The Research Foundation For The State University Of New York by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on November 18, 2026.

How much is award RNS153215UXMNH9 worth?

$198,751 has been obligated on RNS153215UXMNH9.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award